Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab plus platinum and nab-paclitaxel for first-line recurrent or metastatic sinonasal squamous cell carcinoma
ChiCTR2200057343Phase 2Recruiting
- Sponsor
- Cancer Hospital, Chinese Academy of Medical Sciences
- Start
- Mar 2022
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pembrolizumab, cisplatin, carboplatin and paclitaxel in sinonasal squamous cell carcinoma (SNSCC), sponsored by Cancer Hospital, Chinese Academy of Medical Sciences. Primary endpoints: Progression-free survival and Objective response rate. Started Mar 2022; status: recruiting.
02
Drugs
03
Conditions
sinonasal squamous cell carcinoma (SNSCC)
Beyond the preview
Go deeper on ChiCTR2200057343.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200057343.